This is a routine governance filing with no trading implications. The new directors bring relevant medtech experience but their impact on strategy will take quarters to materialize. Monitor next quarterly earnings for any operational updates.
Price Chart
Executive Summary
CONMED filed a routine 8-K reporting the appointment of two new independent directors (Celine Martin and Jeff Mirviss), the appointment of an interim principal accounting officer, the adoption of amended bylaws, and the results of its 2026 annual shareholder meeting where all seven director nominees were elected and both advisory proposals passed. No financial data, earnings, or material business developments were disclosed.
Key Facts
- Board expanded from 7 to 9 directors; Celine Martin (former J&J MedTech executive) and Jeff Mirviss (former Boston Scientific executive) appointed effective July 1, 2026
- Kimberly Lockwood appointed Interim Corporate Controller and Interim Principal Accounting Officer effective June 1, 2026
- Amended and restated bylaws adopted, including updated advance notice deadlines for stockholder proposals (90-120 days before annual meeting anniversary) and director interview requirement
- All seven incumbent directors re-elected at May 18, 2026 annual meeting with strong support (lowest 'for' vote was 93.2% for Charles Farkas)
- Advisory vote on executive compensation and ratification of PwC as auditor both passed with >93% support
- No financial results, guidance, or material agreements disclosed
Financial Impact
No financial figures disclosed in this filing
Risk Factors
- No material risks identified from this routine filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000816956-26-000057 |
| Document: cnmd-20260518.htm | 0000816956-26-000057 |
| Document: a2026nedogarsu.htm | 0000816956-26-000057 |
| Document: pressrelease-martinandmirv.htm | 0000816956-26-000057 |
| Document: 0000816956-26-000057-index-headers.html | 0000816956-26-000057 |
| Document: 0000816956-26-000057-index.html | 0000816956-26-000057 |
| Document: 0000816956-26-000057.txt | 0000816956-26-000057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 17, 2026 18w ago | 8-K | $32.58 $45.01 | ▲ +38.15% | ▲ +37.62% | $47.20 (+44.87%) |
Jun 1, 2026 21w ago | 8-K | $34.65 $32.73 | ▼ −5.54% | ▼ −4.24% | $47.20 (+36.22%) |
May 20, 2026 22w ago | 8-K | $37.01 $32.58 | ▼ −11.97% | ▼ −12.71% | $47.20 (+27.53%) |
Apr 7, 2026 29w ago | DEFA14A | $34.54 $35.88 | ▲ +3.88% | ▼ −5.90% | $47.20 (+36.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers